# CoMind Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/comind-technologies

- Industry: Medical Devices & Equipment
- Headquarters: London, UK
- Website: www.comind.io/
- Total disclosed funding: $125M
- Latest round: Series A (Oct 20, 2025)
- Investors on record: 8

## About

CoMind Technologies Limited is a UK-based company specializing in advanced neurotechnology solutions for non-invasive brain activity monitoring, enhancing clinical care and patient outcomes globally.CoMind Technologies Limited, founded in 2018 and headquartered in London, UK, focuses on neurotechnology innovations that transform brain monitoring methodologies.In October 2025, CoMind Technologies Limited raised USD 60 million in series B funding led by Plural, with participation from Latitude, Entrepreneur First, Angelini Ventures, Octopus Ventures, LocalGlobe, Crane Venture Partners, Backed VC, along with Individuals and other unspecified investors also participated in the round. This funding represents the total amount raised by the company to date, positioning it for future growth in the healthcare sector.CoMind Technologies Limited specializes in developing advanced neurotechnology solutions that offer non-invasive clinical monitoring of brain activity. Their core product provides healthcare professionals with access to a comprehensive range of neurophysiological signals, which are typically difficult to measure through traditional methods. This innovative approach allows doctors to obtain critical information at the patient's bedside, enhancing the overall quality of care. The primary end users of CoMind's products include hospitals, clinics, and research institutions focused on neurology and related fields. The technology is designed for deployment in various geographical markets, including North America, Europe, and parts of Asia, catering to a diverse set of healthcare providers who aim to improve patient outcomes through advanced brain measurement techniques.CoMind Technologies generates revenue primarily through direct sales of its proprietary neurotechnology products to healthcare institutions and clinical partners. The transaction structure is centered around business-to-business agreements, where hospitals and clinics purchase the technology as part of their medical equipment inventory. This business model may include subscriptions for ongoing software updates and support services, ensuring clients receive the latest advancements in neurophysiological monitoring. The pricing strategy reflects the advanced nature of the technology offered, with a focus on long-term partnerships that foster continuous engagement with healthcare providers. Flagship products are designed to address specific needs in clinical settings, thereby enhancing the overall revenue potential through tailored solutions and dedicated customer support. The company aims to expand its market presence in North America, Europe, and parts of Asia, targeting healthcare providers by the end of 2025. The company will use the October 2025 funding to seek US regulatory approval for its first product, complete additional clinical trials, expand its team, and establish manufacturing partnerships.

## Funding rounds

- Series A, Oct 20, 2025, $99M — Octopus Ventures, First Entrepreneurs Fund, Backed VC, LocalGlobe, Crane Venture Partners, Plural, Angelini Ventures
- Series A, Aug 24, 2023, $25M — Octopus Ventures, Entrepreneur First, Backed VC, LocalGlobe, Crane Venture Partners, Angelini Ventures
- Seed, Dec 21, 2021 — Entrepreneur First, Backed VC, LocalGlobe, Crane Venture Partners

## Investors

- Entrepreneur First (https://capitalatlas.ai/funds/entrepreneur-first) — Seed, Series A
- Backed VC (https://capitalatlas.ai/funds/backed-vc) — Seed, Series A
- LocalGlobe (https://capitalatlas.ai/funds/localglobe) — Seed, Series A
- Crane Venture Partners (https://capitalatlas.ai/funds/crane-venture-partners) — Seed, Series A
- Octopus Ventures (https://capitalatlas.ai/funds/octopus-ventures) — Series A
- Angelini Ventures (https://capitalatlas.ai/funds/angelini-ventures) — Series A
- First Entrepreneurs Fund (https://capitalatlas.ai/funds/first-entrepreneurs-fund) — Series A
- Plural (https://capitalatlas.ai/funds/plural) — Series A